{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T07:34:22Z","timestamp":1767339262885,"version":"3.37.3"},"reference-count":72,"publisher":"American Society of Hematology","issue":"12","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,3,25]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Convalescent plasma (CP) from blood donors with antibodies to severe acute respiratory syndrome coronavirus 2 may benefit patients with COVID-19 by providing immediate passive immunity via transfusion or by being used to manufacture hyperimmune immunoglobulin preparations. Optimal product characteristics (including neutralizing antibody titers), transfusion volume, and administration timing remain to be determined. Preliminary COVID-19 CP safety data are encouraging, but establishing the clinical efficacy of CP requires an ongoing international collaborative effort. Preliminary results from large, high-quality randomized trials have recently started to be reported.<\/jats:p>","DOI":"10.1182\/blood.2020008903","type":"journal-article","created":{"date-parts":[[2020,11,17]],"date-time":"2020-11-17T21:43:21Z","timestamp":1605649401000},"page":"1573-1581","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":28,"title":["How should we use convalescent plasma therapies for the management of COVID-19?"],"prefix":"10.1182","volume":"137","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7527-2340","authenticated-orcid":false,"given":"Erica M.","family":"Wood","sequence":"first","affiliation":[{"name":"Transfusion Research Unit, School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia;"},{"name":"Department of Clinical Haematology, Monash Health, Melbourne, VIC, Australia;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4309-9162","authenticated-orcid":false,"given":"Lise J.","family":"Estcourt","sequence":"additional","affiliation":[{"name":"Haematology\/Transfusion Medicine, National Health Service (NHS) Blood and Transplant, Oxford, United Kingdom; and"},{"name":"Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9698-7185","authenticated-orcid":false,"given":"Zoe K.","family":"McQuilten","sequence":"additional","affiliation":[{"name":"Transfusion Research Unit, School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia;"},{"name":"Department of Clinical Haematology, Monash Health, Melbourne, VIC, Australia;"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"issue":"3","key":"2021032515261202300_B1","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.tmrv.2020.04.001","article-title":"Convalescent plasma: therapeutic hope or hopeless strategy in the SARS-CoV-2 pandemic","volume":"34","author":"Sullivan","year":"2020","journal-title":"Transfus Med Rev"},{"issue":"3","key":"2021032515261202300_B2","doi-asserted-by":"crossref","first-page":"102790","DOI":"10.1016\/j.transci.2020.102790","article-title":"Treatment for emerging viruses: convalescent plasma and COVID-19","volume":"59","author":"Brown","year":"2020","journal-title":"Transfus Apher Sci"},{"issue":"4","key":"2021032515261202300_B3","doi-asserted-by":"crossref","first-page":"102858","DOI":"10.1016\/j.transci.2020.102858","article-title":"Passive immunotherapy with convalescent plasma against COVID-19? What about the evidence base and clinical trials?","volume":"59","author":"Garraud","year":"2020","journal-title":"Transfus Apher Sci"},{"issue":"4","key":"2021032515261202300_B4","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1093\/cid\/ciq106","article-title":"Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection","volume":"52","author":"Hung","year":"2011","journal-title":"Clin Infect Dis"},{"issue":"2","key":"2021032515261202300_B5","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1378\/chest.12-2907","article-title":"Hyperimmune IV immunoglobulin treatment: a multicenter double-blind randomized controlled trial for patients with severe 2009 influenza A(H1N1) infection","volume":"144","author":"Hung","year":"2013","journal-title":"Chest"},{"issue":"1","key":"2021032515261202300_B6","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s10096-004-1271-9","article-title":"Use of convalescent plasma therapy in SARS patients in Hong Kong","volume":"24","author":"Cheng","year":"2005","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"4","key":"2021032515261202300_B7","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1172\/JCI138003","article-title":"The convalescent sera option for containing COVID-19","volume":"130","author":"Casadevall","year":"2020","journal-title":"J Clin Invest"},{"issue":"1","key":"2021032515261202300_B8","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1093\/infdis\/jiu396","article-title":"The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis","volume":"211","author":"Mair-Jenkins","year":"2015","journal-title":"J Infect Dis"},{"issue":"3","key":"2021032515261202300_B9","doi-asserted-by":"crossref","first-page":"e409","DOI":"10.1097\/HS9.0000000000000409","article-title":"The emerging role of convalescent plasma in the treatment of COVID-19","volume":"4","author":"Psaltopoulou","year":"2020","journal-title":"HemaSphere"},{"issue":"1","key":"2021032515261202300_B10","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1186\/s13054-020-03163-3","article-title":"Convalescent plasma to treat critically ill patients with COVID-19: framing the need for randomised clinical trials [editorial]","volume":"24","author":"Shankar-Hari","year":"2020","journal-title":"Crit Care"},{"issue":"1","key":"2021032515261202300_B11","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1111\/vox.12973","article-title":"Clinical use of convalescent plasma in the covid-19 pandemic: a transfusion-focussed gap analysis with recommendations for future research priorities","volume":"116","author":"Al-Riyami","year":"2021","journal-title":"Vox Sang"},{"author":"World Health Organization","key":"2021032515261202300_B12","article-title":"Geneva: WHO Coronavirus (COVID-19) Dashboard"},{"issue":"16","key":"2021032515261202300_B13","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1001\/jama.2020.4783","article-title":"Treatment of 5 critically ill patients with COVID-19 with convalescent plasma","volume":"323","author":"Shen","year":"2020","journal-title":"JAMA"},{"issue":"17","key":"2021032515261202300_B14","doi-asserted-by":"crossref","first-page":"9490","DOI":"10.1073\/pnas.2004168117","article-title":"Effectiveness of convalescent plasma therapy in severe COVID-19 patients","volume":"117","author":"Duan","year":"2020","journal-title":"Proc Natl Acad Sci USA"},{"issue":"12","key":"2021032515261202300_B15","doi-asserted-by":"crossref","first-page":"2834","DOI":"10.3324\/haematol.2020.261784","article-title":"Mortality reduction in 46 severe Covid-19 patients treated with hyperimmune plasma. A proof of concept single arm multicenter trial","volume":"105","author":"Perotti","year":"2020","journal-title":"Haematologica"},{"issue":"8","key":"2021032515261202300_B16","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1016\/j.ajpath.2020.05.014","article-title":"Treatment of coronavirus disease 2019 (COVID-19) patients with convalescent plasma","volume":"190","author":"Salazar","year":"2020","journal-title":"Am J Pathol"},{"issue":"5","key":"2021032515261202300_B17","doi-asserted-by":"crossref","first-page":"102875","DOI":"10.1016\/j.transci.2020.102875","article-title":"Clinical efficacy of convalescent plasma for treatment of COVID-19 infections: results of a multicenter clinical study","volume":"59","author":"Abolghasemi","year":"2020","journal-title":"Transfus Apher Sci"},{"author":"US Food and Drug Administration","key":"2021032515261202300_B18","article-title":"Clinical Memorandum: EUA 26382: Emergency Use Authorization (EUA) Request (original request 8\/12\/20; amended request 8\/23\/20)"},{"author":"European Blood Alliance","key":"2021032515261202300_B19","article-title":"Convalescent Plasma (CCP): What Is COVID-19 Convalescent Plasma?"},{"author":"European Blood Alliance","key":"2021032515261202300_B20","article-title":"SUPPORT-E European Project on COVID-19 Convalescent Plasma: EU Commission Allocates \u20ac4M Grant for SUPPORT-E"},{"issue":"9","key":"2021032515261202300_B21","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1016\/j.mayocp.2020.06.028","article-title":"Safety update: COVID-19 convalescent plasma in 20,000 hospitalized patients","volume":"95","author":"Joyner","year":"2020","journal-title":"Mayo Clin Proc"},{"issue":"5","key":"2021032515261202300_B22","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1001\/jama.2020.10044","article-title":"Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial [published correction appears in JAMA. 2020;324(5):519]","volume":"324","author":"Li","year":"2020","journal-title":"JAMA"},{"issue":"3","key":"2021032515261202300_B23","first-page":"357","article-title":"The therapeutic potential of convalescent plasma therapy on treating critically-ill COVID-19 patients residing in respiratory care units in hospitals in Baghdad, Iraq","volume":"28","author":"Rasheed","year":"2020","journal-title":"Infez Med"},{"key":"2021032515261202300_B24","doi-asserted-by":"crossref","first-page":"m3939","DOI":"10.1136\/bmj.m3939","article-title":"Convalescent plasma in the management of moderate Covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial) [published correction appears in BMJ. 2020;371:m4232]","volume":"371","author":"Agarwal","year":"2020","journal-title":"BMJ"},{"article-title":"Convalescent Plasma for COVID-19. A randomized clinical trial","author":"Gharbharan","key":"2021032515261202300_B25","doi-asserted-by":"crossref","DOI":"10.1101\/2020.07.01.20139857"},{"article-title":"Convalescent Plasma for COVID-19: A Multicenter, Randomized Clinical Trial","author":"Avendano-Sola","key":"2021032515261202300_B26","doi-asserted-by":"crossref","DOI":"10.1101\/2020.08.26.20182444"},{"key":"2021032515261202300_B27","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2033700","article-title":"Early high-titer plasma therapy to prevent severe Covid-19 in older adults","author":"Libster","year":"2021","journal-title":"New Engl J Med"},{"article-title":"A randomized trial of convalescent Plasma in Covid-19 severe pneumonia","author":"Simonovich","key":"2021032515261202300_B28","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2031304"},{"author":"Alqahtani","key":"2021032515261202300_B29"},{"author":"Bajpai","key":"2021032515261202300_B30"},{"author":"Balcells","key":"2021032515261202300_B31"},{"author":"Hamdy","key":"2021032515261202300_B32"},{"author":"Ray","key":"2021032515261202300_B33"},{"key":"2021032515261202300_B34","first-page":"CD013600","article-title":"Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review","volume":"10","author":"Chai","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"author":"US Food and Drug Administration","key":"2021032515261202300_B35"},{"issue":"3","key":"2021032515261202300_B36","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.immuni.2020.07.020","article-title":"Distinct early serological signatures track with SARS-CoV-2 survival","volume":"53","author":"Atyeo","year":"2020","journal-title":"Immunity"},{"issue":"6515","key":"2021032515261202300_B37","doi-asserted-by":"crossref","first-page":"eabd4585","DOI":"10.1126\/science.abd4585","article-title":"Autoantibodies against type I IFNs in patients with life-threatening COVID-19","volume":"370","author":"Bastard","year":"2020","journal-title":"Science"},{"author":"REMAP-CAP Statement 12 January 2021","key":"2021032515261202300_B38"},{"author":"RECOVERY Statement 15 Janurary 2021","key":"2021032515261202300_B39"},{"author":"CONCOR-1: A Randomized, Open-Label Trial of CONvalescent Plasma for Hospitalized Adults With Acute COVID-19 Respiratory Illness. Statement 3 February 2021","key":"2021032515261202300_B40"},{"issue":"3","key":"2021032515261202300_B41","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.tmrv.2020.04.002","article-title":"COVID-19 convalescent plasma: now is the time for better science","volume":"34","author":"Dzik","year":"2020","journal-title":"Transfus Med Rev"},{"issue":"16","key":"2021032515261202300_B42","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1182\/blood.2020008230","article-title":"No evidence of SARS-CoV-2 transfusion transmission despite RNA detection in blood donors showing symptoms after donation","volume":"136","author":"Cappy","year":"2020","journal-title":"Blood"},{"issue":"2","key":"2021032515261202300_B43","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.tmrv.2020.02.004","article-title":"COVID-19 and blood safety: help with a dilemma","volume":"34","author":"Dodd","year":"2020","journal-title":"Transfus Med Rev"},{"issue":"4","key":"2021032515261202300_B44","doi-asserted-by":"crossref","first-page":"102817","DOI":"10.1016\/j.transci.2020.102817","article-title":"Position paper on the preparation of immune plasma to be used in the treatment of patients with COVID-19","volume":"59","author":"Accorsi","year":"2020","journal-title":"Transfus Apher Sci"},{"issue":"8","key":"2021032515261202300_B45","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1038\/s41375-020-0914-x","article-title":"Response to \u201cCOVID-19 in persons with haematological cancers\u201d [letter]","volume":"34","author":"Hatzl","year":"2020","journal-title":"Leukemia"},{"issue":"5","key":"2021032515261202300_B46","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.ccell.2020.09.007","article-title":"SARS-CoV-2 viral load predicts mortality in patients with and without cancer who are hospitalized with COVID-19","volume":"38","author":"Westblade","year":"2020","journal-title":"Cancer Cell"},{"issue":"20","key":"2021032515261202300_B47","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1182\/blood.2020008423","article-title":"Convalescent plasma therapy for B-cell-depleted patients with protracted COVID-19","volume":"136","author":"Hueso","year":"2020","journal-title":"Blood"},{"key":"2021032515261202300_B48","doi-asserted-by":"crossref","first-page":"m3249","DOI":"10.1136\/bmj.m3249","article-title":"Clinical characteristics of children and young people admitted to hospital with covid-19 in United Kingdom: prospective multicentre observational cohort study","volume":"370","author":"Swann","year":"2020","journal-title":"BMJ"},{"issue":"11","key":"2021032515261202300_B49","doi-asserted-by":"crossref","first-page":"e28693","DOI":"10.1002\/pbc.28693","article-title":"Convalescent plasma for pediatric patients with SARS-CoV-2-associated acute respiratory distress syndrome","volume":"67","author":"Diorio","year":"2020","journal-title":"Pediatr Blood Cancer"},{"issue":"5","key":"2021032515261202300_B50","doi-asserted-by":"crossref","first-page":"102936","DOI":"10.1016\/j.transci.2020.102936","article-title":"A consideration of convalescent plasma and plasma derivatives in the care of severely-ill patients with COVID-19","volume":"59","author":"Lung","year":"2020","journal-title":"Transfus Apher Sci"},{"issue":"2","key":"2021032515261202300_B51","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1001\/jama.2020.10245","article-title":"Monoclonal antibodies for prevention and treatment of COVID-19","volume":"324","author":"Marovich","year":"2020","journal-title":"JAMA"},{"author":"The REMAP-CAP Investigators. Interleukin-6 receptor antagonists in critically ill patients with Covid-19 \u2013 Preliminary report","key":"2021032515261202300_B52"},{"issue":"16","key":"2021032515261202300_B53","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1001\/jama.2020.18598","article-title":"Change in donor characteristics and antibodies to SARS-CoV-2 in donated blood in the US, June-August 2020","volume":"324","author":"Dodd","year":"2020","journal-title":"JAMA"},{"article-title":"Intravenous immunoglobulin (IVIG) significantly reduces respiratory morbidity in COVID-19 pneumonia: a prospective randomized trial","author":"Sakoulas","key":"2021032515261202300_B54","doi-asserted-by":"crossref","DOI":"10.1101\/2020.07.20.20157891"},{"issue":"16","key":"2021032515261202300_B55","doi-asserted-by":"crossref","first-page":"3971","DOI":"10.1182\/bloodadvances.2020001786","article-title":"Platelets mediate serological memory to neutralize viruses in vitro and in vivo","volume":"4","author":"Schrottmaier","year":"2020","journal-title":"Blood Adv"},{"issue":"1","key":"2021032515261202300_B56","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1186\/s13054-018-2220-9","article-title":"Early therapeutic plasma exchange in septic shock: a prospective open-label nonrandomized pilot study focusing on safety, hemodynamics, vascular barrier function, and biologic markers","volume":"22","author":"Knaup","year":"2018","journal-title":"Crit Care"},{"issue":"1","key":"2021032515261202300_B57","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1186\/s13054-020-03070-7","article-title":"First do no harm-beware the risk of therapeutic plasma exchange in severe COVID-19","volume":"24","author":"Stahl","year":"2020","journal-title":"Crit Care"},{"key":"2021032515261202300_B58","doi-asserted-by":"crossref","first-page":"m3516","DOI":"10.1136\/bmj.m3516","article-title":"Convalescent plasma for covid-19","volume":"370","author":"Estcourt","year":"2020","journal-title":"BMJ"},{"issue":"11","key":"2021032515261202300_B59","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1038\/s41591-020-1077-z","article-title":"COVID-19 clinical trials: learning from exceptions in the research chaos","volume":"26","author":"Tikkinen","year":"2020","journal-title":"Nat Med"},{"author":"WHO Solidarity Trial Consortium","key":"2021032515261202300_B60"},{"author":"International Society of Blood Transfusion","key":"2021032515261202300_B61","article-title":"COVID-19 Resources"},{"author":"World Health Organization, Geneva: 27th WHO regulatory update on COVID-19 (24 January 2021)","key":"2021032515261202300_B62"},{"author":"World Health Organization, Geneva: WHO Blood Regulators\u2019 Network Position Paper on Use of Convalescent Plasma, Serum or Immune Globulin Concentrates as an Element in Response to an Emerging Virus* 2017","key":"2021032515261202300_B63"},{"author":"European Union COVID-19 Convalescent Plasma Database","key":"2021032515261202300_B64"},{"issue":"6","key":"2021032515261202300_B65","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1001\/jama.2020.13042","article-title":"Pooling data from individual clinical trials in the COVID-19 era","volume":"324","author":"Petkova","year":"2020","journal-title":"JAMA"},{"issue":"12","key":"2021032515261202300_B66","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.1111\/trf.16051","article-title":"Blood use and transfusion needs at a large health care system in Washington state during the SARS-CoV-2 pandemic","volume":"60","author":"Pagano","year":"2020","journal-title":"Transfusion"},{"issue":"9","key":"2021032515261202300_B67","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1111\/trf.15995","article-title":"Blood stewardship: Conservation and supply of blood components during the severe acute respiratory syndrome coronavirus 2 pandemic","volume":"60","author":"Vossoughi","year":"2020","journal-title":"Transfusion"},{"issue":"10","key":"2021032515261202300_B68","doi-asserted-by":"crossref","first-page":"e756","DOI":"10.1016\/S2352-3026(20)30186-1","article-title":"Effects of the COVID-19 pandemic on supply and use of blood for transfusion","volume":"7","author":"Stanworth","year":"2020","journal-title":"Lancet Haematol"},{"author":"AABB: 2021 AABB COVID-19 Hospital Transfusion Services Survey Final Report","key":"2021032515261202300_B69"},{"key":"2021032515261202300_B70","doi-asserted-by":"crossref","first-page":"m4072","DOI":"10.1136\/bmj.m4072","article-title":"Convalescent plasma is ineffective for covid-19","volume":"371","author":"Pathak","year":"2020","journal-title":"BMJ"},{"author":"American Society of Hematology","key":"2021032515261202300_B71","article-title":"ASH Comment on Emergency Use Authorization for Convalescent Plasma"},{"author":"National Institutes of Health","key":"2021032515261202300_B72","article-title":"COVID-19 Treatment Guidelines: Convalescent Plasma"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/137\/12\/1573\/1803469\/bloodbld2020008903c.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/137\/12\/1573\/1803469\/bloodbld2020008903c.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T14:57:37Z","timestamp":1697122657000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/137\/12\/1573\/474185\/How-should-we-use-convalescent-plasma-therapies"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,25]]},"references-count":72,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,3,25]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2020008903","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"type":"print","value":"0006-4971"},{"type":"electronic","value":"1528-0020"}],"subject":[],"published":{"date-parts":[[2021,3,25]]}}}